Over 1 billion patients with unmet needs in fatty liver, high cholesterol, and obesity—Purpose Bio delivers safe, oral enzyme therapies to transform care

Market Opportunity:

Over 1 billion people suffer from fatty liver, high cholesterol, obesity, and related cardiometabolic diseases. Existing drugs are systemic, hormonal, costly, and limited by safety and tolerability issues. Purpose Bio addresses this massive unmet need with safe, oral, non systemic enzyme therapies targeting a global market exceeding $100B annually.

Technology:

Purpose Bio’s proprietary engineered enzymes safely fine-tune metabolism with tunable precision—preserving critical signaling pathways while addressing fatty liver, cholesterol, obesity, and the broader $100B+ cardiometabolic market.

Advantages:

  • Oral, safe, non-systemic
  • Unique MOA, Non-hormonal, non-receptor targeting
  • Tunable, new-to-nature precision
  • Preserves signaling pathways
  • Scalable across metabolic diseases

Development Stage:

  • Pre-Clinical

IP Protection:

  • 2 exclusive UCLA application (1 Approved Patent in U.S)
  • 2 fully owned PCT application

Select Press Releases/Publications/Presentations:

  • Named by UCLA among Top Most Promising Life Science Startup
  • Department Of Defense Innovation Award
  • DRAPER Showcase Finalist
  • Los Angeles Most Promising Biotech Companies

Contact:

Website: purposebio.com

Email: lital@purposebio.com

Phone: +1917 488 5553

LinkedIn: linkedin.com/in/litalsh/

Purpose Bio LinkedIn: linkedin.com/company/purposebio

Current Portfolio Companies